Powered by

Merck to gobble biotech drug developer Afferent

Jun 10, 2016 - The Deal Pipeline
Mergers and Acquisitions

In its most sizable deal in over a year, http://pipeline.thedeal.com/tdd/ViewCompany.dl?id=2404502|Merck & Co. (MRK) has agreed to shell out as much as $1.25 billion for http://pipeline.thedeal.com/tdd/ViewCompany.dl?id=2021346|Afferent Pharmaceuticals Inc., a clinical-stage biotechnology company focused on drugs that treat various neurogenic conditions including the chronic cough.

Merck will acquire all outstanding shares of the privately held San Mateo, Calif., company for...